Abiraterone-induced refractory hypokalaemia and torsades de pointes in a patient with metastatic castration-resistant prostate carcinoma: a case report.

Mariam Riad Jeffery Scott Allison Shahla Nayyal AbdulWahab Hritani

Published in: European heart journal. Case reports (2021)

Abiraterone has been widely used in mCRPC since its approval by the Food and Drug Adminstration in 2011. Regulatory guidelines and standardized close QTc and electrolyte monitoring in patients may help prevent fatal arrhythmias associated with abiraterone.

Keyphrases

end stage renal disease
drug induced
prostate cancer
ejection fraction
newly diagnosed
squamous cell carcinoma
small cell lung cancer
prognostic factors
peritoneal dialysis
case report
high glucose
clinical practice
patient reported outcomes
diabetic rats
oxidative stress
risk assessment
endothelial cells